DCBLD1

Across TCGA pan-cancer cohorts, DCBLD1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DCBLD1 data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher DCBLD1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated DCBLD1 expression acts as an unfavorable survival marker, although some lineages such as HNSC and GBM show a favorable association.

PDAC, HNSC, and LSCC are the cancer types where DCBLD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.246	0.590	.004	32	view →
HNSC	DFS	Quartile	All	0.832	0.575	.008	17	view →
LSCC	DFS	Median	II,III,IV	0.667	0.861	.027	3	view →
LUAD	OS	Quartile	All	0.648	1.000	.032	2	view →
GBM	DFS	Tertile	All	0.842	0.631	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DCBLD1–PDAC (DFS)

Open the PDAC breakdown →